|
1
|
De Cecco L, Marchionni L, Gariboldi M,
Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E,
Mezzanzanica D, Turatti F, et al: Gene expression profiling of
advanced ovarian cancer: Characterization of a molecular signature
involving fibroblast growth factor 2. Oncogene. 23:8171–8183. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann NY Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schiff PB and Horwitz SB: Taxol stabilizes
microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA.
77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang S and Houghton PJ: Inhibitors of
mammalian target of rapamycin as novel antitumor agents: From bench
to clinic. Curr Opin Investig Drugs. 3:295–304. 2002.PubMed/NCBI
|
|
6
|
Kurmasheva RT, Huang S and Houghton PJ:
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer.
95:955–960. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mabuchi S, Altomare DA, Connolly DC,
Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC and
Testa JR: RAD001 (Everolimus) delays tumor onset and progression in
a transgenic mouse model of ovarian cancer. Cancer Res.
67:2408–2413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Squillace RM, Miller D, Cookson M,
Wardwell SD, Moran L, Clapham D, Wang F, Clackson T and Rivera VM:
Antitumor activity of ridaforolimus and potential cell-cycle
determinants of sensitivity in sarcoma and endometrial cancer
models. Mol Cancer Ther. 10:1959–1968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takano M, Kikuchi Y, Kudoh K, Goto T,
Furuya K, Kikuchi R, Kita T, Fujiwara K, Shiozawa T and Aoki D:
Weekly administration of temsirolimus for heavily pretreated
patients with clear cell carcinoma of the ovary: A report of six
cases. Int J Clin Oncol. 16:605–609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Foster H, Coley HM, Goumenou A, Pados G,
Harvey A and Karteris E: Differential expression of mTOR signalling
components in drug resistance in ovarian cancer. Anticancer Res.
30:3529–3534. 2010.PubMed/NCBI
|
|
11
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
13
|
Jacob F, Guertler R, Naim S, Nixdorf S,
Fedier A, Hacker NF and Heinzelmann-Schwarz V: Careful selection of
reference genes is required for reliable performance of RT-qPCR in
human normal and cancer cell lines. PLoS One. 8:e591802013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pearce CL, Templeman C, Rossing MA, Lee A,
Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund
KG, et al; Ovarian Cancer Association Consortium. Association
between endometriosis and risk of histological subtypes of ovarian
cancer: A pooled analysis of case-control studies. Lancet Oncol.
13:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brinton LA, Sakoda LC, Sherman ME,
Frederiksen K, Kjaer SK, Graubard BI, Olsen JH and Mellemkjaer L:
Relationship of benign gynecologic diseases to subsequent risk of
ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev.
14:2929–2935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Merritt MA, Green AC, Nagle CM and Webb
PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian
Cancer Study Group. Talcum powder, chronic pelvic inflammation and
NSAIDs in relation to risk of epithelial ovarian cancer. Int J
Cancer. 122:170–176. 2008. View Article : Google Scholar
|
|
17
|
Fagone P, Donia M, Mangano K, Quattrocchi
C, Mammana S, Coco M, Libra M, McCubrey JA and Nicoletti F:
Comparative study of rapamycin and temsirolimus demonstrates
superimposable anti-tumour potency on prostate cancer cells. Basic
Clin Pharmacol Toxicol. 112:63–69. 2013. View Article : Google Scholar
|
|
18
|
Treeck O, Wackwitz B, Haus U and Ortmann
O: Effects of a combined treatment with mTOR inhibitor RAD001 and
tamoxifen in vitro on growth and apoptosis of human cancer cells.
Gynecol Oncol. 102:292–299. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peterson TR, Laplante M, Thoreen CC,
Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an
mTOR inhibitor frequently overexpressed in multiple myeloma cells
and required for their survival. Cell. 137:873–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zitzmann K, Rüden J, Brand S, Göke B,
Lichtl J, Spöttl G and Auernhammer CJ: Compensatory activation of
Akt in response to mTOR and Raf inhibitors - a rationale for
dual-targeted therapy approaches in neuroendocrine tumor disease.
Cancer Lett. 295:100–109. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hisamatsu T, Mabuchi S, Matsumoto Y,
Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H,
Schilder RJ, et al: Potential role of mTORC2 as a therapeutic
target in clear cell carcinoma of the ovary. Mol Cancer Ther.
12:1367–1377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carracedo A, Ma L, Teruya-Feldstein J,
Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma
SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 118:3065–3074. 2008.PubMed/NCBI
|
|
23
|
Durbas M, Horwacik I, Boratyn E, Kamycka E
and Rokita H: GD2 ganglioside specific antibody treatment
downregulates PI3K/Akt/mTOR signaling network in human
neuroblastoma cell lines. Int J Oncol. 47:1143–1159.
2015.PubMed/NCBI
|
|
24
|
Ishikawa D, Takeuchi S, Nakagawa T, Sano
T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al:
mTOR inhibitors control the growth of EGFR mutant lung cancer even
after acquiring resistance by HGF. PLoS One. 8:e621042013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kondo A, Otsuka T, Kuroyanagi G, Yamamoto
N, Matsushima-Nishiwaki R, Mizutani J, Kozawa O and Tokuda H:
Resveratrol inhibits BMP-4-stimulated VEGF synthesis in
osteoblasts: Suppression of S6 kinase. Int J Mol Med. 33:1013–1018.
2014.PubMed/NCBI
|
|
26
|
Zhang M, Zhou X and Zhou K: Resveratrol
inhibits human nasopharyngeal carcinoma cell growth via blocking
pAkt/p70S6K signaling pathways. Int J Mol Med. 31:621–627.
2013.PubMed/NCBI
|
|
27
|
Ip CK, Yung S, Chan TM, Tsao SW and Wong
AS: p70 S6 kinase drives ovarian cancer metastasis through
multicellular spheroid-peritoneum interaction and P-cadherin/b1
integrin signaling activation. Oncotarget. 5:9133–9149. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Beelen K, Opdam M, Severson TM, Koornstra
RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van
Diest PJ, et al: Phosphorylated p-70S6K predicts tamoxifen
resistance in postmenopausal breast cancer patients randomized
between adjuvant tamoxifen versus no systemic treatment. Breast
Cancer Res. 16:R62014. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Avellino R, Romano S, Parasole R, Bisogni
R, Lamberti A, Poggi V, Venuta S and Romano MF: Rapamycin
stimulates apoptosis of childhood acute lymphoblastic leukemia
cells. Blood. 106:1400–1406. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hahn M, Li W, Yu C, Rahmani M, Dent P and
Grant S: Rapamycin and UCN-01 synergistically induce apoptosis in
human leukemia cells through a process that is regulated by the
Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol
Cancer Ther. 4:457–470. 2005.PubMed/NCBI
|
|
31
|
Beuvink I, Boulay A, Fumagalli S,
Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and
Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21
translation. Cell. 120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
